Why did PHASQ stock drop 99% on 09 Jan 2026?

PHASQ stock fell due to thin liquidity, Chapter 11 history, and ongoing clinical and financing uncertainty. Low volume of **2,500** shares amplified the move. Market participants priced in severe downside absent near-term positive catalysts.

What are the main financial metrics for PHASQ stock?

Key metrics: EPS **-2.14**, revenue per share TTM **0.000368**, cash per share **1.421879**, price averages 50/200 days **0.000236/0.000666**, and current price **USD 0.000001**. These show operating losses with intermittent cash cushions.

What does Meyka AI forecast for PHASQ stock?

Meyka AI's forecast model projects a base-case of **USD 0.000100** in 12 months. Versus current **USD 0.000001**, that implies roughly **9,900.00%** upside. Forecasts are model-based projections and not guarantees.

Should investors buy PHASQ stock now?

PHASQ stock is speculative and high risk. Consider it only for tiny, well-sized positions. Wait for clinical readouts, firm financing, or partnership updates before increasing exposure.

US Stocks

PHASQ stock down 99% to $0.000001 on PNK 09 Jan 2026: what traders should watch

ByHuzaifa Zahoor January 9, 2026January 9, 2026

PHASQ stock plunged -99.0% to USD 0.000001 on the PNK exchange during market hours on 09 Jan 2026. We saw volume of 2,500 shares against a 50-day average of 22,310. The move follows a history of Chapter 11 restructuring and continued clinical-stage risk for PhaseBio Pharmaceuticals, Inc. The price collapse reflects near-zero market cap, thin liquidity, and persistent development uncertainty for bentracimab and other pipeline assets